Meet the beaten-down biotech that Wood loves and Wall Street says may soar more than 65% over the coming 12 months. First, ...

On Monday, Purple Biotech Ltd (NASDAQ:PPBT) reported the final results from the randomized Phase 2 study of its lead oncology ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The boost in stock value is primarily attributed to the company’s recent announcement of positive final results from a Phase 2 study of its lead oncology drug, CM24. This milestone positions Purple ...

Shares of Purple Biotech ($PPBT) surged more than 45% on Monday morning, reaching their highest levels since early October.

As breakthroughs in biotechnology accelerate, the sector is primed for significant expansion. With emerging trends like gene ...

This biotech stock is back in a buy zone after a sharp sell-off. The company makes an obesity drug and develops treatments ...

Daiwa Securities Group Inc. lowered its stake in Legend Biotech Co. (NASDAQ:LEGN – Free Report) by 9.3% in the third quarter, ...

智通财经APP获悉，华尔街金融巨头摩根大通近日发布研报称，对于2025年美股市场的生物科技公司 (即Biotech)股价走势持乐观看涨立场，预计Biotech有望跑赢美股大盘，其中美股Biotech领军者之一的福泰制药 (VRTX.US) ...